Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00336973
Status:
COMPLETED
Last Update Posted:
2015-07-23
First Post:
2006-06-13
Brief Title:
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase IV Open-Label Study to Evaluate the Efficacy and Safety of 10 mgkg Raptiva Efalizumab in Adult Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase IV open-label study to evaluate the efficacy and safety of SC efalizumab in adult subjects 18 years of age and older with chronic moderate or worse plaque psoriasis who have had an inadequate response to treatment with an anti-TNF agent The study will consist of a screening period a treatment period and an observation period All subjects will begin in the screening period the length of which is dependent on the previous anti-TNF agent treatment Approximately 100 eligible subjects will receive treatment from Day 0 through Day 168
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None